BI 765883 + gemcitabine + nab-paclitaxel

BI 765883 + gemcitabine + nab-paclitaxel is an experimental combination therapy evaluated for advanced and metastatic pancreatic ductal adenocarcinoma. BI 765883 is a novel, investigational agent developed by Boehringer Ingelheim and was studied in its first-in-human trial both as monotherapy and in combination with standard chemotherapies gemcitabine (a nucleoside analog antimetabolite) and nab-paclitaxel (an albumin-bound paclitaxel formulation). The mechanism of action for BI 765883 itself remains undisclosed publicly, while gemcitabine inhibits DNA synthesis and nab-paclitaxel disrupts microtubule function, both exerting antineoplastic effects. This specific triple combination was developed to explore improved treatment efficacy in pancreatic cancer, with the trial primarily assessing safety, dosing, and preliminary antitumor activity[1][2][3][4].